Comments
Loading...

Cidara Therapeutics Analyst Ratings

CDTXNASDAQ
Logo brought to you by Benzinga Data
$22.39
0.813.75%
At close: -
$22.39
0.000.00%
After Hours: Mar 28, 4:00 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$46.00
Lowest Price Target1
$33.00
Consensus Price Target1
$38.00

Cidara Therapeutics Analyst Ratings and Price Targets | NASDAQ:CDTX | Benzinga

Cidara Therapeutics Inc has a consensus price target of $38 based on the ratings of 8 analysts. The high is $46 issued by Citizens Capital Markets on March 12, 2025. The low is $33 issued by Guggenheim on November 8, 2024. The 3 most-recent analyst ratings were released by Citizens Capital Markets, HC Wainwright & Co., and Needham on March 12, 2025, March 10, 2025, and March 7, 2025, respectively. With an average price target of $38.67 between Citizens Capital Markets, HC Wainwright & Co., and Needham, there's an implied 72.70% upside for Cidara Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Oct 24
2
Nov 24
2
Dec 24
1
Jan
2
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.4
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Citizens Capital Markets
HC Wainwright & Co.
Needham
RBC Capital
WBB Securities

1calculated from analyst ratings

Analyst Ratings for Cidara Therapeutics

Buy NowGet Alert
03/12/2025Buy Now105.45%Citizens Capital Markets
Roy Buchanan36%
→ $46Initiates → Market OutperformGet Alert
03/10/2025Buy Now56.32%HC Wainwright & Co.
Ed Arce60%
$24 → $35MaintainsBuyGet Alert
03/07/2025Buy Now56.32%Needham
Joseph Stringer51%
$35 → $35ReiteratesBuy → BuyGet Alert
01/27/2025Buy NowCantor Fitzgerald
Eric Schmidt31%
Assumes → OverweightGet Alert
12/13/2024Buy Now51.85%RBC Capital
Gregory Renza47%
→ $34Initiates → OutperformGet Alert
12/05/2024Buy Now100.98%WBB Securities
Stephen Brozak77%
$40 → $45MaintainsStrong BuyGet Alert
11/11/2024Buy Now7.19%HC Wainwright & Co.
Ed Arce60%
$24 → $24ReiteratesBuy → BuyGet Alert
11/08/2024Buy Now47.39%Guggenheim
Seamus Fernandez61%
→ $33Initiates → BuyGet Alert
10/22/2024Buy Now7.19%HC Wainwright & Co.
Ed Arce60%
$24 → $24ReiteratesBuy → BuyGet Alert
09/16/2024Buy Now7.19%HC Wainwright & Co.
Ed Arce60%
$24 → $24ReiteratesBuy → BuyGet Alert
08/14/2024Buy Now7.19%HC Wainwright & Co.
Ed Arce60%
→ $24UpgradeNeutral → BuyGet Alert
08/14/2024Buy NowCantor Fitzgerald
Louise Chen56%
Reiterates → OverweightGet Alert
08/14/2024Buy Now11.66%Needham
Joseph Stringer51%
$25 → $25ReiteratesBuy → BuyGet Alert
06/20/2024Buy NowCantor Fitzgerald
Louise Chen56%
Reiterates → OverweightGet Alert
05/16/2024Buy Now11.66%Needham
Joseph Stringer51%
$25 → $25ReiteratesBuy → BuyGet Alert
04/25/2024Buy Now78.65%WBB Securities
Stephen Brozak77%
→ $40MaintainsStrong BuyGet Alert
04/25/2024Buy Now11.66%Needham
Joseph Stringer51%
$3 → $25MaintainsBuyGet Alert
04/25/2024Buy NowCantor Fitzgerald
Louise Chen56%
Reiterates → OverweightGet Alert
04/23/2024Buy NowCantor Fitzgerald
Louise Chen56%
Reiterates → OverweightGet Alert
04/08/2024Buy Now-73.2%HC Wainwright & Co.
Ed Arce60%
$120 → $120MaintainsBuyGet Alert
12/07/2023Buy Now-73.2%HC Wainwright & Co.
Ed Arce60%
$6 → $120ReiteratesBuy → BuyGet Alert
11/06/2023Buy Now-73.2%HC Wainwright & Co.
Ed Arce60%
→ $120ReiteratesBuy → BuyGet Alert
09/22/2023Buy Now-86.6%Needham
Joseph Stringer51%
→ $60ReiteratesBuy → BuyGet Alert
09/22/2023Buy Now-73.2%HC Wainwright & Co.
Ed Arce60%
→ $120ReiteratesBuy → BuyGet Alert
09/08/2023Buy Now-86.6%Needham
Joseph Stringer51%
→ $60ReiteratesBuy → BuyGet Alert
09/07/2023Buy Now-73.2%HC Wainwright & Co.
Ed Arce60%
→ $120ReiteratesBuy → BuyGet Alert
08/07/2023Buy Now-73.2%HC Wainwright & Co.
Ed Arce60%
→ $120Reiterates → BuyGet Alert
08/04/2023Buy Now-86.6%Needham
Joseph Stringer51%
→ $60ReiteratesBuy → BuyGet Alert
08/01/2023Buy Now-73.2%HC Wainwright & Co.
Ed Arce60%
→ $120Reiterates → BuyGet Alert
08/01/2023Buy Now-77.67%Cantor Fitzgerald
Louise Chen56%
→ $100ReiteratesOverweight → OverweightGet Alert
06/26/2023Buy Now-73.2%HC Wainwright & Co.
Ed Arce60%
→ $120ReiteratesBuy → BuyGet Alert
05/15/2023Buy Now-73.2%HC Wainwright & Co.
Ed Arce60%
→ $120ReiteratesBuy → BuyGet Alert
05/12/2023Buy Now-86.6%Needham
Joseph Stringer51%
→ $60ReiteratesBuy → BuyGet Alert
04/18/2023Buy Now-86.6%Needham
Joseph Stringer51%
→ $60Reiterates → BuyGet Alert
03/24/2023Buy Now-73.2%HC Wainwright & Co.
Ed Arce60%
→ $120Reiterates → BuyGet Alert
03/23/2023Buy Now-73.2%HC Wainwright & Co.
Ed Arce60%
$130 → $120MaintainsBuyGet Alert
03/08/2023Buy Now-77.67%Cantor Fitzgerald
Louise Chen56%
→ $100Reiterates → OverweightGet Alert
03/01/2023Buy Now-70.97%HC Wainwright & Co.
Ed Arce60%
→ $130Reiterates → BuyGet Alert
01/25/2023Buy Now-70.97%HC Wainwright & Co.
Ed Arce60%
$120 → $130MaintainsBuyGet Alert
05/12/2022Buy Now-73.2%HC Wainwright & Co.
Ed Arce60%
$150 → $120MaintainsBuyGet Alert

FAQ

Q

What is the target price for Cidara Therapeutics (CDTX) stock?

A

The latest price target for Cidara Therapeutics (NASDAQ:CDTX) was reported by Citizens Capital Markets on March 12, 2025. The analyst firm set a price target for $46.00 expecting CDTX to rise to within 12 months (a possible 105.45% upside). 20 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Cidara Therapeutics (CDTX)?

A

The latest analyst rating for Cidara Therapeutics (NASDAQ:CDTX) was provided by Citizens Capital Markets, and Cidara Therapeutics initiated their market outperform rating.

Q

When was the last upgrade for Cidara Therapeutics (CDTX)?

A

The last upgrade for Cidara Therapeutics Inc happened on August 14, 2024 when HC Wainwright & Co. raised their price target to $24. HC Wainwright & Co. previously had a neutral for Cidara Therapeutics Inc.

Q

When was the last downgrade for Cidara Therapeutics (CDTX)?

A

There is no last downgrade for Cidara Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Cidara Therapeutics (CDTX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cidara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cidara Therapeutics was filed on March 12, 2025 so you should expect the next rating to be made available sometime around March 12, 2026.

Q

Is the Analyst Rating Cidara Therapeutics (CDTX) correct?

A

While ratings are subjective and will change, the latest Cidara Therapeutics (CDTX) rating was a initiated with a price target of $0.00 to $46.00. The current price Cidara Therapeutics (CDTX) is trading at is $22.39, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch